Ipamorelin vs Tesamorelin

The Dose Guy’s verdict

Oct 27, 2026
10 sources

For general GH-axis work, meaning recovery, sleep, and a slow recomp, my pick is ipamorelin, paired with CJC-1295. Tesamorelin wins one job: visceral belly fat, where it has phase 3 trials and an FDA approval and ipamorelin has nothing. It works the other half of the axis, the GHRH slot CJC-1295 fills, so the real choice is the ipamorelin stack against tesamorelin, and the deciding question is whether deep belly fat is your target. If it is, run tesamorelin daily and plan to keep running it.

Which would I take?Ipamorelin, unless belly fat is the target.

How they differ

The biggest difference is receipts. Tesamorelin has phase 3 trials, an approval, and a measured result on the deep abdominal fat that wraps your organs. Ipamorelin has a clean mechanism and no body-composition trial at all. That gap is the whole case for tesamorelin, and it only covers that target: the trials were in people with HIV, and outside that lane its recomp case is borrowed from the same mechanism CJC-1295 runs on.

Mechanically, they sit on opposite sides of the axis. Tesamorelin is a GHRH analog, the release signal your hypothalamus sends. Ipamorelin is a secretagogue that hits the ghrelin receptor and gets your pituitary to release a GH pulse on the spot. That makes them partners as much as rivals: some people run tesamorelin as the GHRH half with ipamorelin on top. There is no reason to run tesamorelin and CJC-1295 together, because they fill the same slot.

For fat loss, tesamorelin is the one with numbers. For muscle, neither builds much you’d see next to training and food; the ipamorelin stack is the cheaper, lower-commitment way to run the GH axis for recovery, and tesamorelin is a daily routine for months that undoes itself when you stop. None of that changes for women; the choice is the target, not who is pinning.

What the research shows

No trial has put the two side by side, and their evidence is not even the same kind. These are different studies in different people, one set in HIV patients, the other in animals and healthy volunteers:

No head-to-head trial of ipamorelin against tesamorelin exists, and ipamorelin has never been tested against a body-composition endpoint in humans.as of Aug 2026

Tesamorelin in people with HIV: a 15.4% treatment effect on visceral fat at 26 weeks versus placebo, and participants continuing to 52 weeks maintained a 17.5% reduction from baseline.JCEM 2010 · pooled phase 3 · n=806

Pooling four RCTs, tesamorelin 2 mg cut visceral fat by 21.47 cm2 and added 1.42 kg of lean body mass versus control.JAIPA 2026 · meta-analysis · 4 RCTs, n=909

The visceral fat improvements were rapidly lost when participants switched from tesamorelin to placebo.JAIDS 2010 · phase 3 · n=404

Twice-daily ipamorelin raised fat-pad weight relative to body weight and raised food intake in mice, while GH itself lowered relative fat mass. A mouse result, and the only body-composition data ipamorelin has. It points the wrong way, but it is not a reason to skip ipamorelin on a cut; MK-677 is the ghrelin-side option whose hunger fights you there.BBRC 2001 · mice · 9 weeks

How people run them

Tesamorelin is 2 mg sub-q once a day, flat, no titration, because that is the dose the trials used. The trials dosed in the morning; empty stomach either way. Plan on six months or more, and plan on it staying daily, because the belly fat comes back when you stop. That makes it a routine, not a course.

The ipamorelin stack is 200–300 mcg of ipamorelin with 100 mcg of no-DAC CJC-1295 in one syringe, pre-bed, on an empty stomach, adding a morning shot if you want more. It is the lower-stakes option: miss a night and you lose a night, not the progress.

Switching from the stack to tesamorelin, drop CJC-1295 and start tesamorelin the next morning; no washout, since they share a slot. Keep ipamorelin pre-bed if you like, as the trigger tesamorelin doesn’t provide. Coming off tesamorelin, go back to the full stack the same night, and expect the visceral fat to drift back, because the stack has no receipt for holding it.

Ipamorelin stack200–300 mcg + CJCPre-bed, empty stomach, one syringe with 100 mcg no-DAC CJC-1295.

Tesamorelin2 mg/daySub-q, morning, empty stomach. Flat dose, the only one with data.

Stack to tesadrop CJC-1295Tesamorelin takes its slot the next morning; ipamorelin can stay pre-bed.

Tesa to stacksame nightNo washout needed; expect the visceral fat to drift back.

Skiptesa + CJC-1295Two GHRH analogs in one slot add sides, not GH.

Side effects, side by side

The same raised-GH signals on both; tesamorelin’s are trial-documented, ipamorelin’s mostly firsthand:

commonJoint pain, muscle aches, and tingling or numb hands, the marks of raised GH. Documented in the tesamorelin trials; the same signs show on the ipamorelin stack when the dose runs high.

commonInjection-site redness and irritation on tesamorelin, more frequent than placebo and not serious in the trials.

commonIpamorelin’s own quirk: a short flush or head-rush right after the shot that passes in minutes.

monitorFasting glucose bumps in the first weeks on tesamorelin and settled with time in the trials. GH nudges it on the ipamorelin stack too. Check it on either if yours runs borderline.

unknownIpamorelin has no long-term human safety data. Tesamorelin has a year of trial data, in people with HIV, not in a lean lifter.